CALIWAY BIOPHARMACEUTICALS CO., LTD.

Caliway Biopharmaceuticals Co., Ltd.

Equities

6919

TW0006919004

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
379 ^TWD	-1.04%		-0.26%	+98.17%

Apr. 25	Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints	CI
Mar. 05	Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease	MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Caliway Biopharmaceuticals Co., Ltd.

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints	Apr. 25	CI
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease	Mar. 04	MT
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease	Feb. 14	CI
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug	Jan. 23	MT
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction	Jan. 23	CI
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug	Jan. 09	MT
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease	Jan. 08	CI
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding	Dec. 15	CI
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study	23-10-02	CI
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study	23-09-20	MT
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7	23-09-13	CI
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite	23-06-28	CI
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index	23-06-19	CI
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	23-05-31	CI
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	23-05-31	CI

Chart Caliway Biopharmaceuticals Co., Ltd.

Duration

Period

Chart Caliway Biopharmaceuticals Co., Ltd.

Company Profile

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CALIWAY BIOPHARMACEUTICALS CO., LTD.	+98.17%	1.63B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Stock Market
Equities
6919 Stock
News Caliway Biopharmaceuticals Co., Ltd.
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW